-
公开(公告)号：US20220227887A1
公开(公告)日：2022-07-21
申请号：US17617781
申请日：2020-06-10
Applicant: ONO PHARMACEUTICAL CO., LTD. , TOKUSHIMA UNIVERSITY
Inventor： Taku OKAZAKI , Daisuke SUGIURA , II-mi OKAZAKI , Shiro SHIBAYAMA
Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.
-
公开(公告)号：US20220025051A1
公开(公告)日：2022-01-27
申请号：US17311148
申请日：2019-12-06
Applicant: ONO PHARMACEUTICAL CO., LTD. , TOKUSHIMA UNIVERSITY
Inventor： Taku OKAZAKI , Daisuke SUGIURA , Takeo MAEDA , Shiro SHIBAYAMA
Abstract: An immunosuppressive agent containing a substance that is selected from anti-CD80 antibodies and anti-PD-L1 antibodies and that promotes binding between PD-L1 and PD-1.
-
公开(公告)号：US20140072576A1
公开(公告)日：2014-03-13
申请号：US14075538
申请日：2013-11-08
Applicant: ONO PHARMACEUTICAL CO., LTD.
Inventor： Masaya KOKUBO , Motoyuki TANAKA , Hiroshi OCHIAI , Yoshikazu TAKAOKA , Shiro SHIBAYAMA
IPC: A61K31/695 , C07D233/64 , A61K45/06 , C07D471/10 , A61K31/435 , A61K31/5377 , C07F7/18 , A61K31/4178
CPC classification number: A61K31/695 , A61K31/4178 , A61K31/435 , A61K31/5377 , A61K45/06 , C07D233/64 , C07D471/10 , C07F7/1804
Abstract: The present invention relates to a compound represented by formula (I): wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.
Abstract translation: 本发明涉及由式（I）表示的化合物：其中所有符号如本文所定义，其盐，其溶剂化物或其前药。 本发明的化合物对CXCR4具有拮抗作用，因此可用作CXCR4介导的疾病的预防和/或治疗剂，例如炎性和免疫疾病（例如类风湿性关节炎，关节炎，视网膜病变，肺纤维化 ，移植器官的排斥等），过敏性疾病，感染（例如，人类免疫缺陷病毒感染，获得性免疫缺陷综合征等），精神神经病，脑疾病，心血管疾病，代谢疾病和癌性疾病（例如， 癌症，癌症转移等）或再生治疗剂。
-
公开(公告)号：US20170320949A1
公开(公告)日：2017-11-09
申请号：US15619269
申请日：2017-06-09
Applicant: ONO PHARMACEUTICAL CO., LTD.
Inventor： Shiro SHIBAYAMA , Masamichi IMAI
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC classification number: C07K16/2809 , A61K39/395 , A61K45/06 , A61K2039/505 , A61K2300/00 , C07K16/2818 , C07K2317/31 , C07K2317/75
Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 μg/kg, and (c) without requiring administration for at least 3 months after the last administration.
-
公开(公告)号：US20140314714A1
公开(公告)日：2014-10-23
申请号：US14245692
申请日：2014-04-04
Applicant: Tasuku Honjo , ONO PHARMACEUTICAL CO., LTD.
Inventor： Tasuku HONJO , Nagahiro MINATO , Yoshiko IWAI , Shiro SHIBAYAMA
IPC: C07K16/18 , A61K38/21 , A61K39/395
CPC classification number: C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
Abstract translation: 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。
-
Patent Agency Ranking
公开(公告)号：US20230256054A1
公开(公告)日：2023-08-17
申请号：US18183878
申请日：2023-03-14
Applicant: ONO PHARMACEUTICAL CO., LTD.
Inventor： Shiro SHIBAYAMA , Hiroshi ARIMA , Takuya SIMBO
CPC classification number: A61K38/177 , A61K45/06 , A61K38/00 , A61K45/00 , A01K67/0276 , A61P35/02 , C07K16/283 , A61K2039/505
Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer includes administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
-
公开(公告)号：US20220372148A1
公开(公告)日：2022-11-24
申请号：US17624502
申请日：2020-07-03
Applicant: ONO PHARMACEUTICAL CO., LTD.
Inventor： Shiro SHIBAYAMA , Takuya SHIMBO
Abstract: An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.
-
公开(公告)号：US20220185885A1
公开(公告)日：2022-06-16
申请号：US17601354
申请日：2020-04-03
Applicant: ONO PHARMACEUTICAL CO., LTD.
Inventor： Shiro SHIBAYAMA , Tomoya TEZUKA , Mark THROSBY , Cornelis Adriaan DE KRUIF , Pieter Fokko VAN LOO , Rinse KLOOSTER , Robertus Cornelis ROOVERS
IPC: C07K16/28
Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.
-
公开(公告)号：US20170051060A1
公开(公告)日：2017-02-23
申请号：US15226848
申请日：2016-08-02
Applicant: Tasuku HONJO , ONO PHARMACEUTICAL CO., LTD.
Inventor： Tasuku HONJO , Nagahiro MINATO , Yoshiko IWAI , Shiro SHIBAYAMA
IPC: C07K16/28 , A61K38/17 , G01N33/50 , C07K14/705
CPC classification number: C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
Abstract translation: 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于癌症或感染治疗。
-
公开(公告)号：US20160158356A1
公开(公告)日：2016-06-09
申请号：US15000869
申请日：2016-01-19
Applicant: Tasuku HONJO , ONO PHARMACEUTICAL CO., LTD.
Inventor： Tasuku HONJO , Nagahiro MINATO , Yoshiko IWAI , Shiro SHIBAYAMA
IPC: A61K39/395 , A61K45/06
CPC classification number: C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.
Abstract translation: 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法，以及用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1，PD-L2的功能的本发明的组合物可用于癌症或感染治疗。
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.02 seconds)
